Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677739 | 0.85 | TDP1 (0.66) | L3MBTL1TDP1GRM5TSHRCASP3 | |
| SCHEMBL3438744 | 0.82 | TDP1 (0.71) | L3MBTL1TDP1TSHRSMN1; SMN2CASP3 | |
| SCHEMBL4633333 | 0.82 | GRM5 (0.66) | L3MBTL1TDP1GRM5TSHRSMN1; SMN2 | |
| SCHEMBL21070012 | 0.82 | RAB9A (0.59) | TSHRSMN1; SMN2CASP3MAPTRAB9A | |
| SCHEMBL31664187 | 0.80 | RAB9A (0.57) | L3MBTL1TDP1TSHRSMN1; SMN2MAPT | |
| SCHEMBL21069568 | 0.80 | RAB9A (0.57) | L3MBTL1TDP1TSHRSMN1; SMN2MAPT | |
| SCHEMBL2743018 | 0.80 | HPGD (0.61) | L3MBTL1TDP1TSHRSMN1; SMN2CASP3 | |
| SCHEMBL25042262 | 0.79 | HPGD (0.58) | L3MBTL1TDP1GRM5TSHRSMN1; SMN2 | |
| SCHEMBL31006333 | 0.79 | HPGD (0.58) | L3MBTL1TDP1GRM5TSHRSMN1; SMN2 | |
| SCHEMBL25042562 | 0.79 | HPGD (0.58) | L3MBTL1TDP1GRM5TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336642-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-10-10 | — | — | US | disclosed |
| CN-118382435-A | 12/15-Lipoxygenase inhibitors | 总医院公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4384161-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | The General Hospital Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023019090-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336642-A1 | INHIBITORS OF 12/15-LIPOXYGENASE | ALOX15, LOX, ALOX12 | L3MBTL1 1899/4885TDP1 4158/4885GRM5 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.